You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

 

Online download statistics by month:

Online download statistics by month: April 2021 to March 2024

AbstractFullPdf
Apr 2021584584271
May 202126426481
Jun 202117717741
Jul 202113913925
Aug 202117017040
Sep 202114314332
Oct 202114314339
Nov 202116216039
Dec 202116916924
Jan 202215916222
Feb 202218018225
Mar 202231031338
Apr 202219219940
May 202222223346
Jun 202224224741
Jul 202217417924
Aug 202218618828
Sep 202213413638
Oct 202212212523
Nov 202213113423
Dec 202212312318
Jan 202312212217
Feb 202314514614
Mar 202310010116
Apr 2023838329
May 2023989924
Jun 202310010014
Jul 2023838324
Aug 2023626217
Sep 2023666615
Oct 2023636311
Nov 2023959814
Dec 202315115122
Jan 2024697022
Feb 2024828215
Mar 202413413550
Total557956311262